Systemic lupus erythematosus (SLE) provides an excellent example of a disease the totality of whose effects needs to be assessed in three ways. Firstly, disease activity needs to be defined by determining which of its clinical features are potentially reversible. Secondly, permanent damage must be distinguished and last but not least the patient's view of the impact of SLE on his/her life needs to be recognised. Over the past 30 y a myriad of attempts have been made to define disease activity. Reviews of these attempts have already appeared.1,2 In essence, several valid and reliable instruments now exist which have been compared on both 'paper' and live patients. Thus the global score indices known as ECLAM (European Community Lupus Activity Measure),' LAI (Lupus Activity Index),' SLAM (Systemic Lupus Activity Measure)' and SLEDAI (Systemic Lupus Erythematosus Disease Activity Index)' may be used almost interchangeably. For a more detailed individual organ/ system index the BILAG index is well established and widely available. 7, 8 It is still a little early to be certain, but the Medical Outcome Survey Short Form 36 (SF-36) is likely to be the optimal choice as the patient life-impact assessment. 9 9 In contrast it is now timely to review the use of a damage index for patients with lupus. Mortality (the worst and total damage) is still an important endpoint in large clinical and epidemiological studies, but it is no longer the main endpoint for most clinical studies, as very large cohorts would be needed to detect statistically significant differences in mortality for example between two treatment groups. Also mortality may ignore significant differences in morbidity between patients. Therefore, the idea of the assess-ment of damage was mooted both in Canada and Europe and the major development in this area followed a meeting in Boston (October 1991) of the Systemic Lupus International Collaborative Clinicians (SLICC) group.&dquo; During a very intense two day meeting the first attempt at producing an internationally agreed index that reflects damage was made. As a basic principle it was agreed that permanent change whether as a consequence of disease activity (for example requirement for dialysis) or lupus treatment (for example steroid induced osteoporosis) would be included. Every type of damage that has occurred since the diagnosis of SLE is recorded. The damage score can thus only remain the same or increase. It was also agreed that for a feature to be regarded as due to damage, the change must have persisted continuously for at least six months, with the exception of irreversibly damaging events such as a definite stroke or myocardial infarction. Damage is ascertained by clinical assessment or simple investigations, such as urinalysis, creatinine level and plain radiographs, which are widely available. Invasive investigations and more complex radiology (for example CT or MRI scan) are not required as they are not universally available. Following discussions with the American College of Rheumatology (ACR), the SLICC damage index has been accepted and approved by the College.
Details of the SLICC/ACR Damage Index and its glossary of terms11,12 are shown in Table 1 . Briefly, damage is assessed in 12 organ systems as the ocular, neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, musculoskeletal, skin, gonadal and endocrine damage and the occurrence of malignancies. Maximum organ scores range between 1 and 7 points, according to their number of items.
In an initial reliability study using 10 lupus, ascertained by clinical assessment and present for at least six months unless otherwise stated. Repeat episodes mean at least six months apart to score 2. The same lesion cannot be scored twice. A precise definition of items is contained in a glossary.
Potential maximum of the total SLICC/ACR Damage Index: 47 points. aAdding up to a total renal damage score of 3 points. among 10 physicians, from lupus clinics in five countries, on the assessment of damage in these patients.l3 Each patient was assessed by six physicians according to a Younden square design, since it was felt that the patients would not tolerate more than six evaluations within the day of the study. While there were differences among patients (P < 0.001), there was no observer difference (P = 0.933) nor order effect (P = 0.261.)
Further studies have assessed the validity of the SLICC/ACR Damage Index. The SLICC group showed in a retrospective study of 42 case histories that there was a larger increase in the total damage score in patients whose disease was active at two time points 5 y apart compared with patients whose disease was inactive at both time points.&dquo; The instrument was also given to 18 individuals who were not members of the SLICC group with instructions to review and assess it. Sixteen of the 17 respondents agreed with the index, which demonstrates content and face validity.&dquo;
We studied retrospectively the disease course within 10 y of diagnosis in an inception cohort of 80 SLE patients from London and surroundings.&dquo; By the end of the study 10 patients had died and six had developed renal failure requiring dialysis. The mean renal damage score 1 y after diagnosis was found to be a significant predictor of dialysis requiring renal failure (P < 0.01 ) and the mean pulmonary score at 1 y significantly predicted death 10 y after diagnosis 15 Afro-Caribbeans and 9 Asians had significantly higher mean renal (P < 0.05) and total damage scores (P < 0.01, using Mann-Whitney rank test) at 10 y. Between Caucasians and Afro-Caribbeans these differences were evident already 5 y after diagnosis (P < 0.05). As these results are in accordance with the literature prior to the use of the SLICC/ ACR Damage Index,'¢21 they support the validity of the pulmonary, renal and total damage score.
In a further study we have investigated the internal consistency and validity of the SLICC/ACR damage index in 141 patients with SLE in a prospective cross sectional setting.22 Renal and neuropsychiatric damage (as well as renal disease activity) were found to be associated significantly with a medication score (Spearman's rank correlation coefficient p = 0.27 and 0.23, P < 0.001). Damage to the musculoskeletal system was associated significantly with limitations in physical functioning as measured with the Medical Outcome Survey Short Form 20 (p = -0.30, P < 0.01). These and the following findings demonstrate further validity for the SLICC/ACR damage index. There were low, but statistically significant correlations between damage and corresponding previous disease activity scores, as measured by the BILAG system, in the cardiovascular (p = 0.25, P < 0.01 ), pulmonary/ respiratory (p = 0.25, P < 0.01 ), peripheral vascular/ vasculitis (p = 0.26, P < 0.01 ) and musculoskeletal system (p = 0.28, P < 0.01). However, there were no significant associations between disease activity in different organ systems. This means that for example musculoskeletal disease activity is likely to be related to musculoskeletal damage but is unlikely to be accompanied by damage in any other organ. The very rare significant associations among activity scores of different organ/systems' or within different organ/ system damage scores correspond to the clinical experience that organ involvement in SLE does not follow one common pattern. In other words the pattern of organs/systems affected will usually differ from one SLE patient to another. Statistically this lack of one common pattern has resulted in a low internal consistency (Cronbach a = 0.35 for the BILAG activity index and a = 0.41 for the SLICC/ ACR damage index) in the above studies.s,22 As a consequence, we suggested that the individual organ damage scores should be analyzed separately as an endpoint in clinical and epidemiological studies because utilizing a total score alone may give limited information.22
Conclusion
In the 5 y since the first draft of the SLICC/ACR damage index was produced, it has gained acceptance by the American College of Rheumatologists and in its present form has been shown to be valid and reliable. As the only instrument of its kind the assessment of damage among SLE patients from different cohorts and in multicentre therapeutic trials is facilitated greatly. It is already being used in a number of studies of therapy and of the financial consequences of having lupus. Several long term studies exploring the rate at which damage accrues have also been established. Future studies may show that in addition to a disease activity index which can guide therapy the SLICC/ACR damage index may be useful for assessing therapeutic efficacy over a long period. Although a paediatric/adolescent version still needs to be produced we strongly recommend the SLICC/ACR damage index to the lupus community at large. ,
